What Clinicians Need to Know About the Development of Long-Acting Formulations

Clin Infect Dis. 2022 Nov 21;75(Suppl 4):S487-S489. doi: 10.1093/cid/ciac749.

Abstract

We encourage readers of this Supplement to find articles that are relevant to the current and future practice of infectious diseases medicine. Access to long-acting products and formulations in low- and middle-income countries remains a key determinant of the impact of these advances on global health.

Keywords: HIV prevention; HIV treatment; long-acting formulations; tuberculosis; viral hepatitis.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Drug Compounding*
  • Humans